These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19717224)

  • 21. Pisa syndrome and laryngeal dystonia induced by novel antipsychotics.
    Miodownik C; Lerner V; Witztum E
    Isr J Psychiatry Relat Sci; 2011; 48(3):195-200. PubMed ID: 22141144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urticaria and angio-oedema due to ziprasidone.
    Akkaya C; Sarandol A; Aydogan K; Kirli S
    J Psychopharmacol; 2007 Jul; 21(5):550-2. PubMed ID: 17446198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probable association between ziprasidone and worsening hypertension.
    Villanueva N; Markham-Abedi C; McNeely C; Diaz FJ; de Leon J
    Pharmacotherapy; 2006 Sep; 26(9):1352-7. PubMed ID: 16945059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive oculogyric crisis during treatment with clozapine: report of three cases.
    Uzun O; Doruk A
    Clin Drug Investig; 2007; 27(12):861-4. PubMed ID: 18020545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-drug overdose risperidone, ziprasidone, valproate, trihexyphenidyl, and clonazepam.
    Rajkumar AP; Jebaraj P; Tharyan P
    J Assoc Physicians India; 2007 Feb; 55():146-8. PubMed ID: 17571746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A patient using ziprasidone with polydipsia, seizure, hyponatremia and rhabdomyolysis.
    Akkaya C; Sarandol A; Sivrioglu EY; Kotan Z; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1535-8. PubMed ID: 16820256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
    Brook S
    J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Medication-related oculogyric crises: a description of four cases and a review of the literature].
    Darling A; Poo P; Perez-Duenas B; Campistol J
    Rev Neurol; 2013 Feb; 56(3):152-6. PubMed ID: 23359076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol.
    Jhee SS; Zarotsky V; Mohaupt SM; Yones CL; Sims SJ
    Ann Pharmacother; 2003 Oct; 37(10):1434-7. PubMed ID: 14519055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ziprasidone- and lithium-induced neuroleptic malignant syndrome.
    Borovicka MC; Bond LC; Gaughan KM
    Ann Pharmacother; 2006 Jan; 40(1):139-42. PubMed ID: 16352776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated acute dystonia following administration of amisulpride and ziprasidone in a patient with iron deficiency.
    Chen HK; Chen CK; Tzeng NS
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1615-6. PubMed ID: 18597910
    [No Abstract]   [Full Text] [Related]  

  • 36. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient.
    Tsai CF; Tsai SJ; Hwang JP
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):797-9. PubMed ID: 16035110
    [No Abstract]   [Full Text] [Related]  

  • 39. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
    Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
    Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.
    Lee CP; Chen AP; Juang YY
    Clin Schizophr Relat Psychoses; 2015; 9(3):141-4. PubMed ID: 23644168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.